Trends in the stage specific incidence of prostate carcinoma in the Detroit Metropolitan area: 1973-1994

Cancer

Volumn 78, Issue 6, 1996, Pages 1260-1266

  Schwartz, Kendra L ^a,c   Severson, Richard K ^a   Gurney, James G ^a   Montie, James E ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c Department of Family Medicine ^*  (United States)

Author keywords

incidence; prostate carcinoma; prostate specific antigen; screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER SCREENING; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EARLY DIAGNOSIS; HEALTH SURVEY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; UNITED STATES;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGE FACTORS; AGED; AGED, 80 AND OVER; CARCINOMA; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; INCIDENCE; MALE; MASS SCREENING; MICHIGAN; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; POISSON DISTRIBUTION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; SEER PROGRAM; URBAN HEALTH;

EID: 0029786815     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960915)78:6<1260::AID-CNCR14>3.0.CO;2-Z     Document Type: Article

References (23)

1. Ries LAG, Miller BA, Hankey BF, Kosary CL, Edwards BK, editors. Cancer Statistics Review 1973-1991: Tables and Graphs. Bethesda (MD) National Cancer Institute, U.S. Dept. of Health and Human Services, 1994 NIH Pub. No. 94-2789.
2. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995;273:548-52.
3. Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK. Prostate cancer screening: what we know and what we need to know. Ann Intern Med 1993;119:914-23.
4. Feightner JW. The early detection and treatment of prostate cancer: the perspective of the Canadian task force on the periodic health examination. J Urol 1994;152:1682-4.
5. Voss JD. Prostate cancer, screening and prostate-specific antigen: promise or peril? J Gen Intern Med 1994;9:468-74.
6. Waterbor JW, Bueschen AJ. Prostate cancer screening (United States). Cancer Causes Control 1995;6:267-74.
7. Handley MR, Stuart ME. The use of prostate specific antigen for prostate cancer screening: a managed care perspective. J Urol 1994;152:1689-92.
8. Woolf SH. Public health perspective: the health policy implications of screening for prostate cancer. J Urol 1994;152:1685-8.
9. Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS. Screening for prostate cancer. A decision analytic view. JAMA 1994;272:773-80.
10. Demers RY, Swanson GM, Weiss LK, Kau TY. Increasing incidence of cancer of the prostate. The experience of black and white men in the Detroit metropolitan area. Arch Intern Med 1994;154:1211-6.
11. Flanders WD, Kleinbaum DG. Basic models for disease occurrance in epidemiology. Int J Epidemiol 1995;24: 1-7.
12. Gilliland F, Becker TM, Smith A, Key CR, Samet JM. Trends in prostate cancer incidence and morality in New Mexico are consistent with an increase in effective screening. Cancer Epidemiol Biomarkers Prev 1994;3:105-11.
13. Corder EH, Chute CG, Guess HA, Beard CM, O'Fallon M, Lieber MM. Prostate cancer in Rochester, Minnesota (USA), from 1935 to 1989: increases in incidence related to more complete ascertainment. Cancer Causes Control 1994;5:207-14.
14. Hagan RA, Bronson RC, Simms SG, Chang JC, Gibson BB. Prostate cancer in Missouri: a trend analysis. Miss Med 1994;91:581-3.
15. Mettlin CJ, Murphy GP, McGinnin LS, Menck HR. The national cancer data base report on prostate cancer. Cancer 1995;76:1104-12.
16. Stephenson RA, Smart CR, Mineau GP, James BC, Janerich DT, Dibble RL. The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induced peak in incidence-data from the Utah cancer registry. Cancer 1995;77:1342-8.
17. Jacobsen SJ, Katusic SK, Berstralh EJ, Oesterling JE, Ohrt D, Klee GC, et al. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA 1995;274:1445-9.
18. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995;273:289-94.
19. Slawin KM, Ohori M, Dillioglugil O, Scardino PT. Screening for prostate cancer: an analysis of the early experience. CA Cancer J Clin 1995;45:134-47.
20. Ohori M, Scardino PT. Early detection of prostate cancer: the nature of cancers detected with current diagnostic tests. Semin Oncol 1994;21:522-6.
21. Smith DS, Catalona WJ. The nature of prostate cancer detected through prostate specific antigen based screening. J Urol 1994;152:1732-6.
22. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995;274:626-31.
23. Johansson JE, Adami HO, Andersson SO, Bergstrom R, Holmber L, Krusemo UB. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 1992;267:2191-6.